US 11,739,142 B2
Bispecific anti-CCL2 antibodies
Jens Fischer, Penzberg (DE); Guy Georges, Penzberg (DE); Anton Jochner, Penzberg (DE); Gregor Jordan, Penzberg (DE); Hubert Kettenberger, Penzberg (DE); Joerg Moelleken, Penzberg (DE); Tilman Schlothauer, Penzberg (DE); Georg Tiefenthaler, Penzberg (DE); Valeria Runza, Penzberg (DE); Meher Majety, Penzberg (DE); Martin Schaefer, Penzberg (DE); Maria Viert, Penzberg (DE); Shu Feng, Singapore (SG); Wei Shiong Adrian Ho, Singapore (SG); Siok Wan Gan, Singapore (SG); Runyi Adeline Lam, Singapore (SG); and Michael Gertz, Basel (CH)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Dec. 16, 2020, as Appl. No. 17/123,465.
Claims priority of application No. 19217665 (EP), filed on Dec. 18, 2019.
Prior Publication US 2021/0188960 A1, Jun. 24, 2021
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/24 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01)] 2 Claims
 
1. An isolated bispecific antibody comprising a first antigen-binding site that binds to a first epitope on human CCL2 and a second antigen-binding site that binds a second epitope on human CCL2,
wherein
A) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:71;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
B) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:71;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:91;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
C) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:71;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:94;
or
D) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:72;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:94;
or
E) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:73;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
F) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:73;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:94;
or
G) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:73;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:92;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
H) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:73;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:91;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
I) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:72;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
J) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:72;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:92;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
K) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:72;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:91;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
L) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:74;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
M) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:74;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:90;
and a VL domain comprising the amino acid sequence of SEQ ID NO:94;
or
N) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:74;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:92;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
O) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:74;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:91;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93;
or
P) i) said first antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:71;
and a VL domain comprising the amino acid sequence of SEQ ID NO:75; and
ii) said second antigen-binding site comprises
a VH domain comprising the amino acid sequence of SEQ ID NO:92;
and a VL domain comprising the amino acid sequence of SEQ ID NO:93.